Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Pharmacological interventions for osteoporosis in people with chronickidneydisease stages 3-5D [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome
Nitric Oxide Decreases Acute Kidney Injury and Stage 3 ChronicKidneyDisease after Cardiac Surgery No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after cardiac surgery.To determine whether administration of nitric oxide reduces the incidence of postoperative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass.Two hundred and forty-four (...) group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronickidneydisease was reduced from 33% in the control group to 21% in the treatment group (RR, 0.64; 95% CI, 0.41-0.99; P = 0.024) and at 1 year, from 31% to 18% (RR, 0.59; 95% CI, 0.36-0.96; P = 0.017). Nitric oxide treatment reduced the overall major adverse kidney events at 30 days (RR, 0.40; 95% CI, 0.18-0.92
Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronickidneydisease. Maintaining long-term vascular access patency is necessary for high quality haemodialysis (HD) treatment of patients with the terminal and most serious stage of chronickidneydisease (CKD) - end-stage kidneydisease (ESKD). Oral supplementation with omega-3 fatty acids (ω-3FA) may help to prevent blockage of the vascular access by reducing the risk of thrombosis and stenosis.To evaluate (...) the efficacy and safety of ω-3FA supplementation versus placebo or no treatment for maintaining vascular access patency in ESKD patients undergoing HD.We searched the Cochrane Kidney and Transplant Register of Studies up to 23 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with ChronicKidneyDisease The clinical benefit of anti-platelet agents in patients with chronickidneydisease (CKD) is uncertain. In addition, the risk-benefit ratio of potent oral P2Y12-adenosine diphosphate (ADP) receptor antagonists (PPAs), namely, prasugrel and ticagrelor, compared with clopidogrel in CKD patients suffering from acute coronary syndrome (ACS
Association of ChronicKidneyDisease With Allopurinol Use in Gout Treatment Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines.To assess the association of allopurinol use in gout with the risk of developing chronickidneydisease stage 3 or higher.A time-stratified propensity score-matched, population-based, prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol (≥300 mg/d) compared with those who did (...) not initiate allopurinol, using the Health Improvement Network (THIN), a United Kingdom general practitioner electronic health records database, was carried out. The data were analyzed using Cox proportional hazards regression. Among adults aged 18 to 89 years with newly diagnosed gout, we propensity score matched 4760 initiators of allopurinol (≥300 mg/d) to the same number of noninitiators of allopurinol, excluding those with chronickidneydisease stage 3 or higher or urate-lowering therapy use before
Sonographic Venous Velocity Index Identifies Patients with ChronicKidneyDisease and Severe Diastolic Dysfunction Diagnosing cardiorenal syndrome (CRS) in patients with chronickidneydisease (CKD) continues to remain challenging in outpatient practice. In this study, we investigate whether a newly developed venous velocity ultrasound index (VVI) can differentiate between patients with CRS and patients with CKD of other cause or normal renal function (NRF).Patients with CRS (n = 30), CKD (n=30 (...) values of >0.6.The newly developed VVI was useful in successfully predicting severe diastolic dysfunction (CRS) in patients with severe kidney injury in outpatient care.
Kidney Damage Biomarkers and Incident ChronicKidneyDisease During Blood Pressure Reduction: A Case-Control Study. Whether the increased incidence of chronickidneydisease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown.To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm Hg) versus the standard (...) in the setting of intensive SBP lowering was accompanied by decreases, rather than elevations, in levels of kidney damage biomarkers and thus may reflect benign changes in renal blood flow rather than intrinsic injury.National Institute for Diabetes and Digestive and KidneyDiseases.
Low protein diets for non-diabetic adults with chronickidneydisease. Chronickidneydisease (CKD) is defined as reduced function of the kidneys present for 3 months or longer with adverse implications for health and survival. For several decades low protein diets have been proposed for participants with CKD with the aim of slowing the progression to end-stage kidneydisease (ESKD) and delaying the onset of renal replacement therapy. However the relative benefits and harms of dietary protein (...) relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi RCTs in which adults with non-diabetic chronickidneydisease (stages 3 to 5) not on dialysis were randomised to receive a very low protein intake (0.3 to 0.4 g/kg/d) compared with a low protein intake (0.5 to 0.6 g/kg/d
PPI Use and Increased Risk of ChronicKidneyDisease "PPI Use and Increased Risk of ChronicKidneyDisease" by Trevor Romo < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Proton pump inhibitors (PPIs) are a class of gastric-acid reducing medications indicated for conditions including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Zollinger (...) -Ellison syndrome, and erosive esophagitis. With 119 million PPI prescriptions filled in 2009, these are currently one of the most commonly prescribed classes of medication. The current list of known side effects for PPIs includes pneumonia, Clostridium difficile , hip fractures, acute interstitial nephritis (AIN), and malabsorption. The purpose of this review is to investigate if PPI use is also associated with an increased risk in developing chronickidneydisease (CKD) Methods: An exhaustive
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with ChronicKidneyDisease: A Randomised Double-Blind Trial Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronickidneydisease are unknown.The UK HARP-III trial (United Kingdom Heart and Renal Protection-III), a randomized double-blind trial, included 414 (...) (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96-1.90), and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly different between randomized groups.Over 12 months, sacubitril/valsartan has similar effects on kidney function and albuminuria to irbesartan, but it has the additional effect of lowering blood pressure and cardiac biomarkers in people with chronickidney disease.URL: http://www.isrctn.com . Unique identifier: ISRCTN11958993.
Do thiazides work in patients with chronickidneydisease? Do Thiazides Work in Patients With ChronicKidneyDisease? – Clinical Correlations Search Do Thiazides Work in Patients With ChronicKidneyDisease? October 4, 2018 4 min read By Hannah Friedman Peer Reviewed It is a commonly seen scenario on the wards: a patient with a past medical history of heart failure and stage 4 chronickidneydisease presents with progressive shortness of breath and worsening lower extremity edema. The patient (...) (Stage 4-5). However, recent literature .  Recent reports estimate that 13.1% of the US population has chronickidneydisease (CKD), with 8% having at least stage 3 CKD.  These patients have a ,  and this risk worsens as the disease progresses. Thiazides and thiazide-like diuretics act on the distal convoluted tubule of the nephron, specifically on the .  This mechanism makes thiazides useful not just as antihypertensives, but also as diuretics in volume-overloaded patients. Thiazides
Treatment of Hypertension in Association With Nondiabetic ChronicKidneyDisease X. Treatment of Hypertension in Association With Nondiabetic ChronicKidneyDisease | Hypertension Canada Guidelines Subgroup Members: Marcel Ruzicka, MD PhD; Sheldon W. Tobe, MD MScCH; Ramesh Prasad, MBBS MSc MA PhD; Michel Vallée, MD PhD; Cedric Edwards, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc (...) disease , target BP is <140/90 mmHg (Grade B). For patients with hypertension and proteinuric chronickidneydisease (urinary protein >500 mg per 24 hours or albumin to creatinine ratio >30 mg/mmol), initial therapy should be an ACE inhibitor (Grade A) or an ARB if there is intolerance to ACE inhibitors (Grade B). Thiazide/thiazide-like diuretics are recommended as additive antihypertensive therapy (Grade D). For patients with chronickidneydisease and volume overload, loop diuretics
Insulin and glucose-lowering agents for treating people with diabetes and chronickidneydisease. Diabetes is the commonest cause of chronickidneydisease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with near-normal kidney function. It is important to characterise existing knowledge of glucose (...) = 28%) and albuminuria (MD -8.14 mg/mmol creatinine, -14.51 to -1.77; I2 = 11%; low certainty evidence). SGLT2 inhibitors may have little or no effect on the risk of cardiovascular death, hypoglycaemia, acute kidney injury (AKI), and urinary tract infection (low certainty evidence). It is uncertain whether SGLT2 inhibitors have any effect on death, end-stage kidneydisease (ESKD), hypovolaemia, fractures, diabetic ketoacidosis, or discontinuation due to adverse effects (very low certainty evidence
ChronickidneydiseaseChronickidneydisease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Chronickidneydisease Last reviewed: February 2019 Last updated: September 2018 Summary Proteinuria or haematuria, and/or a reduction in the glomerular filtration rate, for more than 3 months' duration. The most common causes are diabetes mellitus and hypertension. The majority of people are asymptomatic, and the diagnosis (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronickidneydisease (CKD), also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. KidneyDisease
Left Main Revascularization With PCI or CABG in Patients With ChronicKidneyDisease: EXCEL Trial The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronickidneydisease (CKD) remains unclear.This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal
Evans M, Grams ME, Sang Y, etÂ al., for the ChronicKidneyDisease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625â€“637 [This corrects the article DOI: 10.1016/j.ekir.2018.01.002.].
Phosphate binders for preventing and treating chronickidneydisease-mineral and bone disorder (CKD-MBD). Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronickidneydisease (CKD) with the aim to prevent progression of chronickidneydisease-mineral and bone disorder (CKD-MBD). This is an update of a review first published in 2011.The aim of this review was to assess the benefits and harms of phosphate binders for people (...) with CKD with particular reference to relevant biochemical end-points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronickidneydisease stage 3A): The DERIVE Study Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR], 45-59 mL/min/1.73 m2 ; chronickidneydisease [CKD] stage 3A
Chronickidneydisease Top results for chronickidneydisease - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for chronickidneydisease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials
ChronicKidneyDisease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology Enabled by the ChronicKidneyDisease, Queensland (CKD.QLD) Registry, we aim to outline the structure, implementation, and outcomes of telenephrology clinics for the management of patients with chronickidneydisease (CKD) in rural, regional, and remote areas of the Darling Downs region in Queensland, Australia.This is an observational registry-based study involving adult patients with CKD, attending